idhifa
(enasidenib mesylate)Celgene Corporation
Usage: IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have an IDH2 mutation, confirmed by an FDA-approved test.
10 results
inrebic
(Fedratinib Hydrochloride)Celgene CorporationUsage: INREBIC® is indicated for treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF), including cases post-polycythemia vera or post-essential thrombocythemia.istodax - romidepsin
(Romidepsin)Celgene Corporationonureg
(azacitidine)Celgene CorporationUsage: ONUREG is indicated for the continued treatment of adults with acute myeloid leukemia who have achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) after intensive induction chemotherapy and are unable to complete intensive curative therapy.pomalyst
(pomalidomide)Celgene CorporationUsage: POMALYST is indicated for adult patients with multiple myeloma who have received at least two prior therapies and show disease progression, as well as for treating AIDS-related and non-AIDS-related Kaposi sarcoma in adults following failure of other therapies.reblozyl - luspatercept injection, powder, lyophilized, for solution
(Luspatercept)Celgene Corporationrevlimid
(Lenalidomide)Celgene CorporationUsage: REVLIMID is indicated for adult patients with multiple myeloma (MM), myelodysplastic syndromes (MDS), mantle cell lymphoma (MCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL). It is used in combination with dexamethasone, rituximab products, or as maintenance therapy post-transplant. Not recommended for chronic lymphocytic leukemia (CLL).thalomid - thalidomide capsule
(Thalidomide)Celgene Corporationvidaza - azacitidine injection, powder, lyophilized, for solution
(Azacitidine)Celgene Corporationzeposia
(ozanimod hydrochloride)Celgene CorporationUsage: ZEPOSIA is indicated for the treatment of relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting, and active secondary progressive disease) and moderately to severely active ulcerative colitis in adults.